相关实验视频

Updated: May 6, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

血IFN-γ可能会预测HER2-阳性晚期乳腺癌患者的pyrotinib疗效

Jinghao Jia¹, Jing Wang^1,2, Xuemin Yao¹

¹Department of Chemoradiotherapy, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China.

Biomedical reports

|June 12, 2025

概括

早期对HER2阳性晚期乳腺癌 (ABC) 的皮罗替尼治疗可能会改善无进展生存率 (PFS). 血IFN-γ水平的增加显示出预后价值,而后期的皮罗替尼使用和更高的IL-8水平与较差的PFS有关.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

皮洛提尼布用于治疗HER2阳性晚期乳腺癌 (ABC).
皮罗丁尼布疗效的预测标记是有限的.
确定可靠的生物标志物对于优化治疗至关重要.

研究的目的:

探索对HER2-阳性ABC患者的pyrotinib治疗的预测性临床因素.
在接受pyrotinib的患者中研究血清细胞因子的预后潜力.
确定与无进展生存 (PFS) 相关的生物标志物.

主要方法:

一项前性观察性研究,对58名 HER2 阳性ABC 患者进行了治疗,这些患者接受了 pyrotinib.
血细胞因子水平 (IL-6,IL-8,IL-10,IL-17,IFN-γ) 在治疗前后测量.
与治疗线和细胞因子水平相关的无进展生存 (PFS) 的分析.

主要成果:

与第三线或后一线 (17.0 vs 9.5 个月) 相比,二线皮罗替尼治疗显示PFS有所改善.
血IL-8水平升高与更差的PFS相关 (9.4 vs. 14.0个月).
血IFN-γ水平增加与较长的PFS (13.0个月与11.0个月) 相关联.
多变量分析确定了后期的皮洛替尼和降低的IFN-γ作为PFS的独立风险因素.

结论:

早期应用皮罗替尼可能会增强HER2阳性ABC患者的PFS,特别是在对trastuzumab耐药的病例中.
血IFN-γ水平显示了皮洛替尼治疗患者的潜在预后价值.
需要进一步的研究来证实对整体存活率的影响.

关键词:

不良事件不良事件不良事件临床疗效临床疗效细胞因子细胞因子人类表皮生长因子受体2-阳性乳腺癌干扰素-γ-γ 的作用.皮罗丁尼比 (pyrotinib) 是一种酸盐.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...